Acquisitions24 Nov 2025, 06:41 pm
Eris Lifesciences to Acquire Remaining 30% Stake in Subsidiary Swiss Parenterals Limited for INR 423.3 Crores
AI Summary
Eris Lifesciences Ltd. has announced that its Board of Directors has approved the acquisition of the remaining 30% of the total share capital of Swiss Parenterals Limited, a subsidiary of the Company, from Mr. Naishadh Shah for a total purchase consideration of INR 423,30,00,000. The acquisition will be discharged by the Company by way of issuance of up to 23,06,372 equity shares of the Company on a preferential basis to Mr. Naishadh Shah. Swiss Parenterals Limited is a pharmaceuticals company incorporated in 1997 with a history of increasing turnover, and has a presence in over 80 countries worldwide.
Key Highlights
- Eris Lifesciences to acquire the remaining 30% stake in its subsidiary Swiss Parenterals Limited.
- Total purchase consideration of INR 423.3 crores for the acquisition.
- Consideration to be discharged by issuing up to 23,06,372 equity shares on a preferential basis to Mr. Naishadh Shah.
- Swiss Parenterals Limited is a pharmaceuticals company with a history of increasing turnover and a presence in over 80 countries worldwide.
- Acquisition aimed at fully consolidating the Company's position, enhancing operational synergy, and strengthening long-term strategic presence.